Skip to content
Recall Observatory FDA recall evidence

Drug product

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

D-0511-2025

June 30, 2025

Class II

Product summary

Firm
Breckenridge Pharmaceutical, Inc.
Event
Event 97179
Status
Ongoing
Classification
Class II
Quantity
12,242 30-count bottles
Official record key
drug-enforcement:D-0511-2025

Official wording

Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Code information: Lot # 230199, Exp. Date 01/31/2026

Distribution pattern: U.S. Nationwide

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    N-nitroso-duloxetine impurity
  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations